EC Number   |
Inhibitors |
Structure |
|---|
    1.1.1.51 | (2,4-dihydroxyphenyl)-phenylmethanone |
remaining 17beta HSD3 activity: 1.1% |
   |
| 1.1.1.51 | (2,4-dihydroxyphenyl)-phenylmethanone |
(2,4-dihydroxyphenyl)-phenylmethanone leads to inhibition of testosterone synthesis in freshly isolated mouse and rat testis tissue |
|
| 1.1.1.51 | (3a,5a)-3-[[(2R,5S)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl]-2,5-dimethylpiperazin-1-yl]methyl]-17-methylideneandrostan-3-ol |
- |
|
| 1.1.1.51 | (3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one |
i.e. RM-532-105 |
|
| 1.1.1.51 | (3alpha,5alpha)-3-[(2,5-dimethyl-4-{[2-(trifluoromethyl)phenyl]sulfonyl}piperazin-1-yl)methyl]-3-hydroxyandrostan-17-one |
the inhibitor RM-532-105 seems to have difficulties in penetrating inside the testis and is concentrated in the testicular capsule. Therefore it is unable to inhibit the 17bets-HSD3 located inside the testis. At a higher concentration, RM-532-105 significantly decreases the level of testosterone and dihydrotestosterone in rat plasma, in vivo effects of the inhibitor in testis and plasma, detailed overview |
|
| 1.1.1.51 | (4-(2,4-dichlorophenyl)piperazin-1-yl)(morpholino)methanone |
- |
|
| 1.1.1.51 | (4-(2-chlorophenyl)piperazin-1-yl)(morpholino)methanone |
- |
|
| 1.1.1.51 | (4-(2-methoxyphenyl)piperazin-1-yl)(morpholino)methanone |
- |
|
| 1.1.1.51 | (4-(3-chlorophenyl)piperazin-1-yl)(morpholino)methanone |
- |
|
| 1.1.1.51 | (4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)(morpholino)methanone |
- |
|
